• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.

作者信息

Okuno Takae, Arakawa Sayaka, Yoshida Tatsuya, Ohe Yuichiro

机构信息

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.

出版信息

Lung Cancer. 2020 May;143:95-96. doi: 10.1016/j.lungcan.2020.03.016. Epub 2020 Mar 18.

DOI:10.1016/j.lungcan.2020.03.016
PMID:32209253
Abstract
摘要

相似文献

1
Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.奥希替尼在一名伴有软脑膜转移和EGFR罕见S768I突变患者中的疗效。
Lung Cancer. 2020 May;143:95-96. doi: 10.1016/j.lungcan.2020.03.016. Epub 2020 Mar 18.
2
Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation.奥希替尼治疗1例无T790M突变的EGFR+非小细胞肺癌软脑膜转移患者的临床疗效分析
Ann Palliat Med. 2019 Nov;8(5):525-531. doi: 10.21037/apm.2019.10.13.
3
Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.奥希替尼治疗 EGFR 突变型非小细胞肺癌伴 EGFR 酪氨酸激酶抑制剂预处理性脑膜转移的疗效。
Target Oncol. 2018 Aug;13(4):501-507. doi: 10.1007/s11523-018-0581-2.
4
Successful Treatment with Osimertinib and Chemotherapy in a Non-Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis.奥希替尼联合化疗成功治疗1例伴有EGFR突变和脑膜癌病的非小细胞肺癌患者
J Thorac Oncol. 2018 Nov;13(11):e219-e220. doi: 10.1016/j.jtho.2018.05.023.
5
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM).表皮生长因子受体突变阳性非小细胞肺癌伴脑膜转移患者中 80 毫克奥希替尼的 II 期疗效和安全性（BLOSSOM）。
J Clin Oncol. 2024 Aug 10;42(23):2747-2756. doi: 10.1200/JCO.24.00708. Epub 2024 Jun 3.
6
Detection of Meningeal Metastasis in the Cerebrospinal Fluid in Lung Adenocarcinoma: Case Report.肺腺癌脑脊液中脑膜转移的检测：病例报告
Clin Lung Cancer. 2020 Sep;21(5):e493-e496. doi: 10.1016/j.cllc.2020.04.010. Epub 2020 Apr 15.
7
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.奥希替尼治疗表皮生长因子受体突变阳性非小细胞肺癌伴脑膜转移患者：BLOOM 研究。
J Clin Oncol. 2020 Feb 20;38(6):538-547. doi: 10.1200/JCO.19.00457. Epub 2019 Dec 6.
8
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.阿法替尼帮助克服 NSCLC 伴脑膜转移患者奥希替尼后继发性耐药，该患者存在获得性 EGFR L718Q 突变：一例报告。
BMC Cancer. 2019 Jul 17;19(1):702. doi: 10.1186/s12885-019-5915-7.
9
Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.曲美替尼克服了 EGFR 突变型肺癌脑膜转移模型中 KRAS-G12V 诱导的奥希替尼耐药。
Cancer Sci. 2021 Sep;112(9):3784-3795. doi: 10.1111/cas.15035. Epub 2021 Jul 22.
10
Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid.基于脑脊液中EGFR T790M耐药突变的检测，用奥希替尼治疗一名非小细胞肺癌患者。
Lung Cancer. 2017 Dec;114:111-112. doi: 10.1016/j.lungcan.2017.10.010. Epub 2017 Oct 28.

引用本文的文献

1
Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysiss.奥希替尼与经治的非小细胞肺癌软脑膜转移患者预后改善相关：一项系统评价和荟萃分析。
Heliyon. 2024 Apr 17;10(9):e29668. doi: 10.1016/j.heliyon.2024.e29668. eCollection 2024 May 15.
2
Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation.在携带罕见表皮生长因子受体突变的非小细胞肺癌患者中，阿法替尼治疗后的临床结果不一致。
Front Oncol. 2022 Nov 8;12:999606. doi: 10.3389/fonc.2022.999606. eCollection 2022.
3
uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors.
晚期非小细胞肺癌中的罕见改变以及对多种酪氨酸激酶抑制剂敏感性的结构洞察
Front Pharmacol. 2022 Sep 16;13:976731. doi: 10.3389/fphar.2022.976731. eCollection 2022.
4
Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches.实体瘤的软脑膜转移：诊断与分子方法的最新进展
Cancers (Basel). 2021 Jun 9;13(12):2888. doi: 10.3390/cancers13122888.